162 related articles for article (PubMed ID: 31099068)
1. Targeted Notch1 inhibition with a Notch1 antibody, OMP-A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression.
Ahmed AA; Robinson T; Palande M; Escara-Wilke J; Dai J; Keller ET
J Cell Biochem; 2019 Oct; 120(10):16946-16955. PubMed ID: 31099068
[TBL] [Abstract][Full Text] [Related]
2. Antiandrogen abiraterone and docetaxel treatments affect Notch1, Jagged1 and Hes1 expressions in metastatic prostate cancer cells.
Soylu H; Kırca M; Avcı S; Ozpolat B; Ustunel I
Exp Mol Pathol; 2021 Apr; 119():104607. PubMed ID: 33482170
[TBL] [Abstract][Full Text] [Related]
3. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.
Silkenstedt E; Arenas F; Colom-Sanmartí B; Xargay-Torrent S; Higashi M; Giró A; Rodriguez V; Fuentes P; Aulitzky WE; van der Kuip H; Beà S; Toribio ML; Campo E; López-Guerra M; Colomer D
J Exp Clin Cancer Res; 2019 Nov; 38(1):446. PubMed ID: 31676012
[TBL] [Abstract][Full Text] [Related]
4. Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
Cui D; Dai J; Keller JM; Mizokami A; Xia S; Keller ET
Clin Cancer Res; 2015 Oct; 21(20):4619-29. PubMed ID: 26202948
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.
Mohamed AA; Tan SH; Xavier CP; Katta S; Huang W; Ravindranath L; Jamal M; Li H; Srivastava M; Srivatsan ES; Sreenath TL; McLeod DG; Srinivasan A; Petrovics G; Dobi A; Srivastava S
Mol Cancer Res; 2017 Oct; 15(10):1308-1317. PubMed ID: 28607007
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of Notch1 by gamma-secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780.
Wang M; Wu L; Wang L; Xin X
Biochem Biophys Res Commun; 2010 Feb; 393(1):144-9. PubMed ID: 20117093
[TBL] [Abstract][Full Text] [Related]
7. Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel.
Yu W; Li J; Wang Q; Wang B; Zhang L; Liu Y; Tang M; Xu G; Yang Z; Wang X; Zhang J; Liu Y; Shi G
Prostate; 2019 Aug; 79(11):1304-1315. PubMed ID: 31212367
[TBL] [Abstract][Full Text] [Related]
8. A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma.
Herrera-Rios D; Li G; Khan D; Tsiampali J; Nickel AC; Aretz P; Hewera M; Suwala AK; Jiang T; Steiger HJ; Kamp MA; Muhammad S; Hänggi D; Maciaczyk J; Zhang W; Kahlert UD
Sci Rep; 2020 Oct; 10(1):16218. PubMed ID: 33004830
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
[TBL] [Abstract][Full Text] [Related]
10. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
11. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
Zhang CC; Yan Z; Zong Q; Fang DD; Painter C; Zhang Q; Chen E; Lira ME; John-Baptiste A; Christensen JG
Stem Cells Transl Med; 2013 Mar; 2(3):233-42. PubMed ID: 23408105
[TBL] [Abstract][Full Text] [Related]
14. Emodin inhibits the proliferation of PC3 prostate cancer cells in vitro via the Notch signaling pathway.
Deng G; Ju X; Meng Q; Yu ZJ; Ma LB
Mol Med Rep; 2015 Sep; 12(3):4427-4433. PubMed ID: 26081222
[TBL] [Abstract][Full Text] [Related]
15. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
16. Gamma-secretase complex-dependent intramembrane proteolysis of CD147 regulates the Notch1 signaling pathway in hepatocellular carcinoma.
Yong YL; Zhang RY; Liu ZK; Wei D; Shang YK; Wu J; Zhang ZY; Li C; Chen ZN; Bian H
J Pathol; 2019 Oct; 249(2):255-267. PubMed ID: 31215640
[TBL] [Abstract][Full Text] [Related]
17. Recent advances on NOTCH signaling in T-ALL.
Tzoneva G; Ferrando AA
Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746
[TBL] [Abstract][Full Text] [Related]
18. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.
Dantas-Barbosa C; Bergthold G; Daudigeos-Dubus E; Blockus H; Boylan JF; Ferreira C; Puget S; Abely M; Vassal G; Grill J; Geoerger B
Anticancer Drugs; 2015 Mar; 26(3):272-83. PubMed ID: 25486598
[TBL] [Abstract][Full Text] [Related]
20. siRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells.
Ye QF; Zhang YC; Peng XQ; Long Z; Ming YZ; He LY
Asian Pac J Cancer Prev; 2012; 13(6):2485-9. PubMed ID: 22938409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
